No Prescription |
 |
 | ||
|
RASTINON Orinase |
|
| ||
No Prescription » Prescription Drugs 14 » RASTINON Orinase Tolbutamide is used to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) particularly in people whose diabetes cannot be controlled by diet alone. Tolbutamide lowers blood sugar by stimulating the pancreas to secrete insulin and helping the body use insulin efficiently. The pancreas must produce insulin for this drug to work. Tolbutamide is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood).Tolbutamide comes in tablets to take by mouth. It is usually taken several times a day. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take tolbutamide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Buy RASTINON Orinase and other Prescription Drugs 14 products online at Medstore. 924
About RASTINON Orinase: Product Type: Prescription Drugs 14 RASTINON ( Orinase Generic Tolbutamide ) RASTINON (Orinase Generic Tolbutamide) Orinase Generic Tolbutamide 500mg Tabs 10 Orinase Generic Tolbutamide RASTINON
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
